Key result
TAVI establishes standard alternative to SAVR, expanding into moderate- and low-risk patients.
Answers are grounded in this paper and cite their sources.
TAVI is a rapidly advancing, standardized alternative to surgical aortic valve replacement with expanding indications, though ongoing technical refinements are needed to minimize procedural complications.
Transcatheter aortic valve implantation (TAVI) has evolved from a challenging intervention to a standardized, simple, and streamlined procedure with over 350,000 procedures performed in over 70 countries. It is now a novel alternative to surgical aortic valve replacement in patients with intermediate surgical risk and its indications have been expanded to cohorts with bicuspid aortic valves, low surgical risk, and younger age and fewer comorbidities. Attention should be paid to further reducing remaining complications, such as paravalvular aortic regurgitation, conduction abnormalities, cardiac tamponade, and stroke. The aim of this review is to provide an overview on the rapidly changing field of TAVI treatment and to explore past achievements, current issues, and future perspectives of this treatment modality.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2018) conducted a review in Severe aortic valve stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve implantation has evolved into a standardized alternative to surgical aortic valve replacement, with expanding indications for moderate and low-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: